These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 25450648)

  • 1. Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database.
    Sacco R; Mismas V; Granito A; Musettini G; Masi G; Caparello C; Vivaldi C; Felder M; Bresci G; Fornaro L;
    Int J Biol Markers; 2015 Feb; 30(1):e65-72. PubMed ID: 25450648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management.
    Faloppi L; Scartozzi M; Bianconi M; Svegliati Baroni G; Toniutto P; Giampieri R; Del Prete M; De Minicis S; Bitetto D; Loretelli C; D'Anzeo M; Benedetti A; Cascinu S
    BMC Cancer; 2014 Feb; 14():110. PubMed ID: 24552144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area.
    Li MX; Zhao H; Bi XY; Li ZY; Yao XS; Li H; Huang Z; Han Y; Zhou JG; Zhao JJ; Zhang YF; Zhao DB; Cai JQ
    Oncotarget; 2016 Dec; 7(52):86630-86647. PubMed ID: 27880930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib.
    Faloppi L; Bianconi M; Giampieri R; Sobrero A; Labianca R; Ferrari D; Barni S; Aitini E; Zaniboni A; Boni C; Caprioni F; Mosconi S; Fanello S; Berardi R; Bittoni A; Andrikou K; Cinquini M; Torri V; Scartozzi M; Cascinu S;
    Oncotarget; 2015 Oct; 6(33):35087-94. PubMed ID: 26397228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
    Negri FV; Dal Bello B; Porta C; Campanini N; Rossi S; Tinelli C; Poggi G; Missale G; Fanello S; Salvagni S; Ardizzoni A; Maria SE
    Liver Int; 2015 Aug; 35(8):2001-8. PubMed ID: 25559745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
    Dig Dis; 2014; 32(6):705-10. PubMed ID: 25376287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.
    Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
    Dig Dis; 2014; 32(6):733-9. PubMed ID: 25376291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.
    Kim GA; Shim JH; Yoon SM; Jung J; Kim JH; Ryu MH; Ryoo BY; Kang YK; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    J Vasc Interv Radiol; 2015 Mar; 26(3):320-9.e6. PubMed ID: 25612807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma.
    Ogasawara S; Chiba T; Ooka Y; Suzuki E; Inoue M; Wakamatsu T; Tawada A; Yokosuka O
    PLoS One; 2016; 11(8):e0161303. PubMed ID: 27537374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management.
    Scartozzi M; Faloppi L; Bianconi M; Giampieri R; Maccaroni E; Bittoni A; Del Prete M; Loretelli C; Belvederesi L; Svegliati Baroni G; Cascinu S
    PLoS One; 2012; 7(3):e32653. PubMed ID: 22461886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L; Su H; Shao H; Xu K; Liang S; Liu J
    Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
    Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
    Estfan B; Byrne M; Kim R
    Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
    Sacco R; Bargellini I; Ginanni B; Bertini M; Faggioni L; Federici G; Romano A; Bertoni M; Metrangolo S; Altomare E; Parisi G; Tumino E; Scaramuzzino A; Bresci G; Bartolozzi C
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):869-75. PubMed ID: 22845401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
    Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
    J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Xu L; Gao H; Huang J; Wang H; Zhou Z; Zhang Y; Li S; Chen M
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1032-9. PubMed ID: 25639513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of serum insulin-like growth factor-1 in hepatocellular carcinoma.
    Elmashad N; Ibrahim WS; Mayah WW; Farouk M; Ali LA; Taha A; Elmashad W
    Asian Pac J Cancer Prev; 2015; 16(2):613-9. PubMed ID: 25684496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib.
    Zheng YB; Zhan MX; Zhao W; Liu B; Huang JW; He X; Fu SR; Zhao Y; Li Y; Hu BS; Lu LG
    Med Oncol; 2014 Oct; 31(10):209. PubMed ID: 25182707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
    Llovet JM; Decaens T; Raoul JL; Boucher E; Kudo M; Chang C; Kang YK; Assenat E; Lim HY; Boige V; Mathurin P; Fartoux L; Lin DY; Bruix J; Poon RT; Sherman M; Blanc JF; Finn RS; Tak WY; Chao Y; Ezzeddine R; Liu D; Walters I; Park JW
    J Clin Oncol; 2013 Oct; 31(28):3509-16. PubMed ID: 23980090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.